<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093025</url>
  </required_header>
  <id_info>
    <org_study_id>TS121-US201</org_study_id>
    <nct_id>NCT03093025</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Patients With Major Depressive Disorder With an Inadequate Response to Current Antidepressant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical R&amp;D Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as
      an adjunctive treatment for patients with major depressive disorder with an inadequate
      response to current antidepressant Treatment (SSRI, SNRI or bupropion).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in MADRS total score from Baseline to End of Treatment estimated for 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAM-A)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in HAM-A total score from Baseline to End of Treatment estimated for 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Depression Questionnaire (SDQ)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in SDQ total score from Baseline to End of Treatment estimated for 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Severity (CGI-S)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in CGI-S score from Baseline to End of Treatment estimated for 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of MADRS responders (≥ 50% reduction in total score) estimated for 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Improvement (CGI-I)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of CGI-I improvers (&quot;Very much improved&quot; or &quot;Much improved&quot;) estimated for 8 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>TS-121 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-121 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-121 10 mg</intervention_name>
    <description>Orally taken once daily</description>
    <arm_group_label>TS-121 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-121 50 mg</intervention_name>
    <description>Orally taken once daily</description>
    <arm_group_label>TS-121 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally taken once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult males and females between 18 and 65 years of age inclusive (at time of initial
             informed consent)

          2. Patients with a current diagnosis of MDD by DSM-5, confirmed through a structured
             interview using MINI

          3. Patients who receive the same antidepressant (SSRI, SNRI or bupropion monotherapy) for
             at least 6 weeks of continuous treatment with at least 4 weeks on a fixed dose

          4. Patients who willing to remain on the same primary SSRI, SNRI or bupropion and fixed
             dose throughout the course of the study

          5. Patients who meet the total score on the HAM-D as listed below

               1. HAM-D ≥ 18 at Screening

               2. HAM-D ≥ 18 at Baseline

          6. Body Mass Index (BMI) ≥ 18 and ≤ 38 kg/m2

        Exclusion Criteria:

          1. Patients with inadequate response to ≥2 prior antidepressant treatments (not including
             current antidepressant) of at least 4 weeks duration each for the current episode

          2. Patients whose current depressive episode is diagnosed with psychotic features,
             catatonic features, post-partum (primary onset), or is secondary to a general medical
             disorder

          3. Patients with a diagnosis of any of the following DSM-5 class disorders

               1. Schizophrenia spectrum and other psychotic disorders

               2. Bipolar and related disorders

               3. Anxiety disorders [Co-morbid GAD and SAD will be allowed in the study if the
                  primary diagnosis is MDD, and if in the opinion of the investigator, the comorbid
                  anxiety is not likely to interfere with the subject's ability to participate in
                  the trial or affect study outcome]

               4. Obsessive-compulsive and related disorders

               5. Trauma- and Stressor-related disorders

          4. Patients who received electroconvulsive therapy (ECT) within 12 months of Screening,
             received more than one course of ECT in their lifetime or plan to receive ECT during
             the study

          5. Patients who received repetitive transcranial magnetic stimulation (rTMS) within 12
             months of Screening or plan to receive rTMS during the study

          6. Patients who plan to initiate or terminate cognitive or behavioral psychotherapy or
             alter the frequency of ongoing therapy during this study

          7. Patients who have attempted suicide within the past 6 months

          8. Patients with history or presence of intellectual disability, pervasive developmental
             disorder, cognitive disorder, neurodegenerative disorder, or brain injury

          9. Patients with any history or complication of convulsive disorder

         10. Patients who are undergoing treatment with psychotropic medications, benzodiazepines,
             metyrapone, lithium and/or corticosteroids

         11. Patients who are taking moderate to strong CYP3A4 inhibitors/inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoji Yasuda</last_name>
    <role>Study Chair</role>
    <affiliation>Taisho Pharmaceutical R&amp;D Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taisho Pharmaceutical R&amp;D Inc.</last_name>
    <phone>888-602-0203</phone>
    <email>ClinicalTrials@taisho-rd.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Woodland Research Northwest</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PAREXEL Early Phase Clinical Unit</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy East</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Care</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chicago Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Behavioral Health Hospital</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwest Research Group - St. Charles Psychiatric Associates</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Global Medical Institutes</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grayline Clinical Drug Trials</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Adjunctive Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

